Metabolome Analysis in Patients With Rheumatoid Arthritis

NCT ID: NCT02960958

Last Updated: 2018-01-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-11-20

Study Completion Date

2019-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate discriminant metabolites in urine from patients with rheumatoid arthritis (RA) from healthy individuals. Then we determine if the patient's metabolic fingerprint could predict the development or flare-up of RA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Compare metabolites between RA patients and healthy individuals.

1. Collection urine sample
2. Assessing urine metabolites by 1H NMR spectroscopy
3. Analyzing the relationships between metabolites and clinical variables

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

RheumatoId Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients with rheumatoid arthritis meet 2010 American College of Rheumatology/European League against Rheumatism classification criteria.

Exclusion Criteria

* Comorbid with other autoimmune diseases
* Confirmed with amyloidosis
* Chronic kidney disease (estimated GFR \< 60 ml/min/1.73m2)
* Chronic liver disease
* Thyroid disease
* Pregnancy
* Solid tumor/hematologic malignancy within 5 years
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Catholic University of Korea

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jung Hee Koh

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jung Hee Koh, MD

Role: PRINCIPAL_INVESTIGATOR

Seoul St.Mary's hospital, The Catholic university of Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CiRAD1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.